Enhancing cancer treatment by targeting dying cells during radiotherapy
Targeting apoptotic cells to enhance radiotherapy
['FUNDING_R01'] · STANFORD UNIVERSITY · NIH-10910914
This study is looking at a new way to make radiation therapy work better for people with advanced prostate cancer by using tiny particles to help target and treat dying cancer cells, which could lead to better results without harming healthy tissue.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | STANFORD UNIVERSITY (nih funded) |
| Locations | 1 site (STANFORD, UNITED STATES) |
| Trial ID | NIH-10910914 on ClinicalTrials.gov |
What this research studies
This research focuses on improving the effectiveness of radiotherapy for cancer patients by developing a new therapeutic strategy that targets apoptotic cells, which are cells undergoing programmed cell death. The approach utilizes a novel nanotechnology to deliver radiosensitizers directly to these cells, enhancing the tumor-killing effects of radiation without increasing the dose to surrounding healthy tissues. By specifically targeting these dying cells, the research aims to improve treatment outcomes for patients with advanced prostate cancer and potentially other malignancies. The study will involve the development and testing of new prodrug radiosensitizers designed to work in conjunction with radiotherapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with advanced prostate cancer who are undergoing or are candidates for radiotherapy.
Not a fit: Patients with early-stage cancer or those not receiving radiotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments with fewer side effects, improving survival rates and quality of life for patients undergoing radiotherapy.
How similar studies have performed: Previous research has shown promise in using targeted approaches to enhance radiotherapy, suggesting that this novel method could be a significant advancement in cancer treatment.
Where this research is happening
STANFORD, UNITED STATES
- STANFORD UNIVERSITY — STANFORD, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: RAO, JIANGHONG — STANFORD UNIVERSITY
- Study coordinator: RAO, JIANGHONG
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acute Radiation Syndrome, Advanced Cancer